Details for Patent: 8,487,093
✉ Email this page to a colleague
Which drugs does patent 8,487,093 protect, and when does it expire?
Patent 8,487,093 protects RECARBRIO and is included in one NDA.
This patent has sixty-eight patent family members in thirty-eight countries.
Summary for Patent: 8,487,093
| Title: | .beta.-lactamase inhibitors |
| Abstract: | Substituted bicyclic beta-lactams of Formula I: (I), are .beta.-lactamase inhibitors, wherein a, X, R.sup.1 and R.sup.2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with .beta.-lactam antibiotics. In particular, the compounds can be employed with a .beta.-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to .beta.-lactam antibiotics due to the presence of the .beta.-lactamases. |
| Inventor(s): | Blizzard; Timothy A. (Princeton, NJ), Chen; Helen (Marlboro, NJ), Gude; Candido (Staten Island, NY), Hermes; Jeffrey D. (Warren, NJ), Imbriglio; Jason (Piscataway, NJ), Kim; Seongkon (Holmdel, NJ), Wu; Jane Y. (Marlboro, NJ), Mortko; Christopher J. (Hoboken, NJ), Mangion; Ian (Cranford, NJ), Rivera; Nelo (New Milford, NJ), Ruck; Rebecca T. (Jersey City, NJ), Shevlin; Michael (Plainfield, NJ) |
| Assignee: | Merck Sharp & Dohme Corp. (Rahway, NJ) |
| Application Number: | 12/812,763 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,487,093
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msd Merck Co | RECARBRIO | cilastatin sodium; imipenem; relebactam | POWDER;INTRAVENOUS | 212819-001 | Jul 16, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI) | ⤷ Try a Trial | ||
| Msd Merck Co | RECARBRIO | cilastatin sodium; imipenem; relebactam | POWDER;INTRAVENOUS | 212819-001 | Jul 16, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) | ⤷ Try a Trial | ||
| Msd Merck Co | RECARBRIO | cilastatin sodium; imipenem; relebactam | POWDER;INTRAVENOUS | 212819-001 | Jul 16, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI) | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,487,093
| PCT Information | |||
| PCT Filed | January 15, 2009 | PCT Application Number: | PCT/US2009/031047 |
| PCT Publication Date: | July 23, 2009 | PCT Publication Number: | WO2009/091856 |
International Family Members for US Patent 8,487,093
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2009206119 | ⤷ Try a Trial | |||
| Brazil | PI0906871 | ⤷ Try a Trial | |||
| Canada | 2712783 | ⤷ Try a Trial | |||
| China | 101918407 | ⤷ Try a Trial | |||
| China | 102827067 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
